share_log

BRIEF-Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In Phase 2 Social Anxiety Disorder Prevail Study

reuters ·  Oct 31, 2021 19:14

Nov 1 (Reuters) - Bionomics Ltd BNO.AX :

* RECEIVES FDA CLEARANCE OF IND FOR EVALUATION OF BNC210 IN A PHASE 2 SOCIAL ANXIETY DISORDER PREVAIL STUDY

Source text for Eikon: ID:nASX50fDqk Further company coverage: BNO.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment